Ham­mered by crit­ics, NewLink strikes back with pos­i­tive PhII in­dox­i­mod da­ta — and shares rock­et up

Few biotechs have in­spired the kind of love-hate re­la­tion­ship that NewLink Ge­net­ics $NLNK seems to pro­voke among the bulls and bears in the biotech in­vest­ment com­mu­ni­ty fol­low­ing its IDO work with pas­sion­ate self-in­ter­est.

Ear­li­er this year, the sen­ti­ment ran dis­tinct­ly along the bear/hate ar­gu­ment, born out by some dis­ap­point­ing da­ta and Genen­tech’s de­ci­sion to punt their part­nered IDO1 ther­a­py. It al­so didn’t help that their can­cer vac­cine flopped bad­ly in 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER